Medical University of South Carolina

Institutional Biosafety Committee Meeting Minutes

Meeting Date	Thursday, December 11, 2025
Meeting Time	12:05 PM –1:23 PM
Meeting Type	Teams Meeting
IBC Members Present	1. Caroline Westwater, Ph.D., (IBC Chair) 2. John Woodward, Ph.D. (IBC Vice Chair) 3. Christina Voelkel-Johnson, Ph.D., (BSO) 4. Lisa Steed, Ph.D., (IBC Member) 5. Carlene Brandon, MS. (Local Non-affiliated Member) 6. Aimee McRae-Clar, Pharm.D., BCPP (IBC Alternate Member; Office of Research Integrity Director) 7. Logan Patterson, Ph.D. (IBC Member)
Quorum	Number of Members Present (Voting): 7 Number of Members Not Present: 4 Late Arrival of Voting Members: 0 Early Departure of Voting Members:0
Other Individuals in Attendance	Michael Smith, Ph.D., (IBC Manager) Gloriane Schnabolk Ph.D., (IACUC & IBC Senior Administrator)
Call to Order	The IBC Chair called the meeting to order at 12:05 PM
Conflicts of Interests	The IBC Chair reminded all members present to identify any conflicts of interest before each registration is reviewed.
Review and Approval of Previous Meeting Minutes	November 13, 2025, IBC meeting minutes were discussed and approved. Voting: (Total =7, For =7, Opposed =0, Abstain = 0).
Review of Prior Business	Discussed Dr. Eldridge, DVM will be rejoining the IBC as the Animal Expert; Second Regional Listening Session on NIH Efforts to Modernize and Strengthen Biosafety Oversight on December 17, 2025; and on-campus tick@lab training
New IBC Registration and Amendments for Review (repeat for each registration)	

Protocol #	IBC-25-344
PI Name	Peterson, Yuri
Study Title	Mechanistic Probes to Study Immune Responses in Periodontal Disease
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☒ RG2 microbes ☐ Biological toxins

	☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other		
rDNA Category	N/A		
Genetically modified microbes or vectors	Aggregatibacter actinomycetemcomitans, Candida albicans		
Transgene expression	N/A		
Highest BSL	BSL2, ABSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:7	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-345
PI Name	Langdon, Casey
Study Title	Disrupted protein subcellular localization in human cancer
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☒ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-D4b
Genetically modified microbes or vectors	Retro/Lentiviral vectors
Transgene expression	EWSR1::FLI1, CAS9, PTEN PAX7, AKT1, AKT2, AKT3, XPO1 BACH1 HMOX1, KPNA2, KPNB1, RAN, ATR (with biochemical EWSR1::WT1 (both -KTS and +KTS isoforms), WT1 (both -KTS

	and +KTS isoforms), EWSR1::ATF1, ATF1, PAX3::FOXO1, CIC::DUX4, NANOG, LMNA, iSce-I, CDT1, GMNN, RHEB, JUN, KRAS, NRAS, HRAS, RANGAP1, JUNB, FOS, PIK3CA, PIK3CB, PIK3CG, PIK3CD, RPTOR, RPS6KB1 (p70S6K), RPS6, MYOD1. luciferase, GFP, mCherry, DR-GFP, CymR, CuO, TetR, TRE, Kusabira-Orange 2, Amazi green, CFP, NR0B1, NF-kB, AP-1, NFAT, TurboID.		
Highest BSL	BSL2, ABSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Voelkel-Johnson	Second:	Steed
Votes			
For:7	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-349
PI Name	Hoffman, Stan
Study Title	Hoffman - Preparation of Recombinant Proteins
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a
Genetically modified microbes or vectors	N/A
Transgene expression	Aggrecan, Periostin, Versican

Highest BSL	BSL1
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☒ BSL1 ☐ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☒ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Woodward
Votes			
For:7	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-350
PI Name	Banik, Narendra
Study Title	Amelioration of Inflammation and Neurodegeneration in Multiple Sclerosis Model
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☒ Biological toxins - **Pertussis toxin** ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	N/A
Genetically modified microbes or vectors	N/A
Transgene expression	N/A
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒

	Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Woodward	Second:	Voelkel-Johnson
Votes			
For:7	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-354
PI Name	Engevik, Mindy
Study Title	Growing stool and clinically isolated microbes
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☒ RG1 microbes ☒ RG2 microbes ☐ Biological toxins ☐ Gene modified rodent cells ☐ Gene modified human cells ☐ Other
rDNA Category	N/A
Genetically modified microbes or vectors	Human stool microbes: Clostridium species, Clostridioides difficile, Fusobacterium species, Klebsiella species, Acinetobacter species, Candida species, Akkermansia species, Streptococcous species, Enterococcus specie, Lactobacillus and Bifidobacterium
Transgene expression	N/A
Highest BSL	BSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐
Motion	☐ Straight approval

	☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Steed
Votes			
For:7	Against:0	Abstained:0	Recused:0

Meeting Adjournment	The IBC Chair called for the meeting to be adjourned at 1:23 PM